Clinical Scorecard: Evaluating Multiple Ileal and Colonic Strictures: Should Crohn’s Disease Always Be Considered?

At a Glance

Key Highlights

• Metastatic tumors to the gastrointestinal tract can mimic Crohn’s disease clinically and radiologically, complicating diagnosis.
• Endoscopic biopsies may show nonspecific inflammation and fail to detect submucosal metastatic infiltration, necessitating surgical histology for definitive diagnosis.
• Comprehensive diagnostic approach integrating clinical history, imaging (CT, MRE, ultrasound), endoscopy, histopathology, and biochemical markers is essential to differentiate Crohn’s disease from metastatic disease.

Guideline-Based Recommendations

Diagnosis

• Consider metastatic disease in differential diagnosis of intestinal strictures when inflammatory bowel disease markers are inconclusive or marginal.
• Use multimodal imaging including CT, magnetic resonance enterography, and intestinal ultrasound to assess extent and characteristics of strictures.
• Perform colonoscopy with biopsies but recognize limitations in detecting submucosal infiltrative diseases.
• Integrate clinical presentation, biochemical markers (CRP, fecal calprotectin), and histology to guide diagnosis.
• Exclude infectious causes such as tuberculosis with appropriate testing (e.g., QuantiFERON-TB Gold).

Management

• Tailor treatment based on definitive diagnosis: lifelong anti-inflammatory and immunosuppressive therapy for Crohn’s disease versus oncological therapies for metastatic cancer.
• Surgical intervention may be necessary for symptom relief or diagnosis when clinical deterioration occurs.
• Initiate systemic cancer therapies such as CDK4/6 inhibitors and hormone therapy in cases of breast cancer metastases.

Monitoring & Follow-up

• Regular imaging follow-up (CT scans) to assess disease stability or progression in metastatic cases.
• Clinical monitoring of symptoms and biochemical markers to evaluate treatment response.
• Multidisciplinary oncological and gastroenterological follow-up to optimize patient outcomes.

Risks

• Misdiagnosis of metastatic disease as Crohn’s disease can delay appropriate oncological treatment.
• Invasive procedures carry risks but may be necessary for definitive diagnosis.
• Potential for clinical deterioration if underlying malignancy is not promptly identified and treated.

Patient & Prescribing Data

Patients with gastrointestinal strictures initially suspected as Crohn’s disease but later diagnosed with metastatic breast cancer.

Oncological treatment with ribociclib (CDK4/6 inhibitor) and letrozole showed stable disease and good tolerance at one-year follow-up.

Clinical Best Practices

• Maintain a broad differential diagnosis in patients with intestinal strictures, especially when clinical, biochemical, and histological findings are discordant.
• Use a multidisciplinary approach involving gastroenterologists, pathologists, radiologists, surgeons, and oncologists for comprehensive evaluation.
• Recognize that negative endoscopic biopsies do not exclude submucosal metastatic infiltration.
• Incorporate biochemical markers such as fecal calprotectin and CRP to assess inflammatory activity and guide suspicion.
• Promptly investigate and treat underlying malignancies when suspected to improve patient outcomes.

References

• European Crohn’s and Colitis Organization (ECCO) Guidelines